Israel

Index
Globenewswire

Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in Major Parts of Europe and in Israel

Globenewswire

Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States

Globenewswire

Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Globenewswire

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025

Globenewswire

Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease

Globenewswire

Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan

Globenewswire

Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial

Globenewswire

Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference

Globenewswire

Teva to Present at the Jefferies London Healthcare Conference

Globenewswire

Yossi Carmil to Step Down as CEO After Nearly 20 Years

Globenewswire

Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition

Globenewswire

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as Well as

Globenewswire

Teva Statement on European Commission Decision; Company to Appeal

Globenewswire

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA

Globenewswire

Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate

Globenewswire

Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024

Globenewswire

Minovia Therapeutics Announces FDA Clearance of IND Application for a Phase Ib Clinical Trial of MNV-201 in Low Risk Myelodysplastic Syndrome

Globenewswire

Cellebrite Patents its Remote Mobile Collection Capabilities for Businesses

Globenewswire

Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia

Globenewswire

Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia

Globenewswire

REE Automotive Announces Global Manufacturing Agreement with Leading Automotive Supplier Motherson Group Making Strategic Investment in a $45.35 Million Registered Direct Offering Led By M&G

Globenewswire

Cellebrite Enhances Investigative Analytics Solution with Amazon Web Services (AWS)

Globenewswire

Teva to Present at the Bank of America 2024 Global Healthcare Conference

Globenewswire

Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Globenewswire

Tabnine Expands Platform Partnerships to Provide Unparalleled Flexibility and Control in Deploying AI Software Development Tools